Celltrion Goes It Alone With First Solo US Biosimilar Launch
Vegzelma Is The Fourth FDA-Approved Bevacizumab Rival To Avastin
Celltrion is taking a major step forward in the US with its first direct launch of a biosimilar through its own front-end operation. The Korean firm’s Vegzelma rival to Avastin will be looking to compete with multiple other versions of bevacizumab already in the market.
